Latest updates for Bimeda

Fresh curated links around Bimeda are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • <![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to
  • Protecting welfare, productivity and performance in flocks this autumn
  • Miebo 20$ otc Europe and 750$ WAC U.S.A.

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

pharmexec.com /1 week ago

&lt;![CDATA[M&amp;A Roundup: DualityBio &amp; Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

Read source
agriland.ie /3 days ago

Protecting welfare, productivity and performance in flocks this autumn

As autumn approaches, many of us are reviewing flock health plans and considering how best to protect sheep from external parasites to enhance productivity and welfare. The Irish g...

Read source
cafepharma.com /1 week ago

Miebo 20$ otc Europe and 750$ WAC U.S.A.

Miebo 20$ otc Europe and 750$ WAC U.S.A. Anonymous (not verified) Sat, 08/29/2026 - 09:42 field_thread_url https://cafepharma.com/boards/threads/miebo-20-o...

Read source
pharmexec.com /3 weeks ago

&lt;![CDATA[M&amp;A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration wit...

Read source
pharmexec.com /1 week ago

&lt;![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]&gt;

Read source
fiercebiotech.com /1 week ago

Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies

Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to treat disease through the selective degradation of pathog...

Read source
genengnews.com /1 week ago

Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciences

Based in Cambridge, MA, Merida develops biologic drugs that are engineered to selectively degrade pathogenic autoantibodies linked to a number of immune-mediated conditions. Merida...

Read source
pharmexec.com /4 weeks ago

&lt;![CDATA[Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutics for alvelestat ]]&gt;

Read source
brownfieldagnews.com /1 month ago

The first cattle vaccine for Theileria is now available to help producers combat a deadly tick-borne disease

The first-ever cattle vaccine to address Theileria is now available.   Dr. Alan Young, the founder and Chief Technology Officer for Medgene, says it is administered in two doses. “...

Read source
pharmexec.com /1 week ago

&lt;![CDATA[Roundup: Alteogen Enters Option &amp; License Agreement with Novartis, NewBiologix &amp; Synastra Form BioTe...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Sources covering Bimeda

cafepharma.com

Recent coverage from public sources
Public source

brownfieldagnews.com

Recent coverage from public sources
Public source

feeds.feedburner.com

Recent coverage from public sources
Public source

agriland.ie

Recent coverage from public sources
Public source

fiercebiotech.com

Recent coverage from public sources
Public source

pharmexec.com

Recent coverage from public sources
Public source